Abstract. Zinc (Zn) deficiency is important for inducing nucleotide-binding domain and leucine-rich repeat-containing family, pyrin domain-containing-3 (NLRP3) inflammasome activation in macrophages. However, its function in the NLRP3 inflammasome activation of peritoneal mesothelial cells (PMCs) remains to be elucidated. In the present study, the human PMC (HPMC) line HMrSV5 was co-treated with high glucose and either ZnSO4 or a Zn chelator. The activity of the NLRP3/caspase-1 inflammasome was assessed via western blot analysis, immunofluorescence, reverse transcription-quantitative polymerase chain reaction and ELISA. In addition, the activity of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway was detected using western blotting, and the level of reactive oxygen species (ROS) was assessed by 2,7-dichlorofluorescein fluorescence and flow cytometry. It was found that Zn supplementation inhibited HG-induced NLRP3 inflammasome activation in the HPMCs by attenuating ROS production. Further experiments revealed that Zn supplementation inhibited the HG-induced production of ROS through activation of the Nrf2 antioxidant pathway. These results indicated that Zn inhibited NLRP3 inflammasome activation in the HG-treated HPMCs by activating the Nrf2 antioxidant pathway and reducing the production of ROS.
Introduction
Peritoneal dialysis (PD) is a key model of renal replacement therapy for end-stage renal disease (1) . The peritoneal membrane is covered with a monolayer of mesothelial cells, which exhibit characteristics of epithelial cells, act as a permeability barrier, and produce a variety of cytokines involved in the regulation of peritoneal permeability and local host defense (1, 2) . Conventional PD solutions contain glucose as an osmotic agent for peritoneal dialysis fluids, which include commercially available 1.5, 2.5 and 4.25% glucose solutions (3). However, long-term exposure to the conventional PD solutions with high concentrations of glucose and glucose degradation products may activate various inflammatory cytokines and growth factors, which can result in damage to human peritoneal mesothelial cells (HPMCs), including high glucose (HG)-induced profibrotic and proinflammatory reactions (4, 5) .
The nucleotide-binding domain and leucine-rich repeat-containing family, pyrin domain-containing-3 (NLRP3) inflammasome is an important component of the innate immune system and is composed of NLRP3, apoptosis-associated speck-like protein containing a CARD (ASC) and procaspase-1. The NLRP3 inflammasome senses endogenous and exogenous danger signals, including lipopolysaccharide (LPS) and HG, resulting in the activation of caspase-1 and subsequent activation of cytokines interleukin (IL)-1β, IL-18 and IL-33 (6) . This trigger sustained inflammation and has been associated with the HG-containing peritoneal dialysis-associated proinflammatory reaction, and may be an effective therapeutic target for preventing HG-induced profibrotic and proinflammatory reactions to PMCs (7) .
Zinc (Zn) is an essential trace element, which is important for various cellular functions, including apoptosis, signal transduction, transcription, differentiation and replication, in all organ systems and during embryonic development (8) (9) (10) (11) (12) . Several studies have demonstrated that Zn supplementation inhibits fibrosis in animal models and human chronic inflammatory diseases, including liver fibrosis, myocardial fibrosis, vasculitis, perivascular fibrosis and cystic fibrosis (13) (14) (15) (16) . Zn deficiency has been reported to be associated with NLRP3 inflammasome activation and the production of IL-1β in macrophages (17) . However, the effect of Zn on HG-induced NLRP3 inflammasome activation in HPMCs remains to be fully elucidated. To address these questions, the present study investigated the effect of Zn on HG-induced NLRP3 inflammasome activation in HPMCs in vitro. To examine the mechanism, the effects of Zn on the production of reactive oxygen species (ROS) and activity of the nuclear factor erythroid 2-related factor 2 (Nrf2) antioxidant pathway were measured.
Materials and methods
Reagents. Penicillin-streptomycin (5,000 U/ml penicillin; 5,000 U/ml streptomycin) and fetal bovine serum (FBS) were obtained from Gibco; Thermo Fisher Scientific, Inc. (Waltham, MA, USA). ZnSO 4 was obtained from Xinhua Pure Chemical Industries (Shenyang, China). Zn chelator N, N, N' , N'-tetrakis (2-pyridylmethyl) ethylenediamine (TPEN) was obtained from Sigma; Merck Millipore (Darmstadt, Germany). The ECL kit was purchased from Pierce; Thermo Fisher Scientific, Inc.). All reagents used were trace element analysis grade.
Cell culture. The HPMC line HMrSV5 was provided by Professor Huimian Xu of The First Affiliated Hospital of China Medical University (Shenyang, China) and cultured in RPMI-1640 medium (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% FBS. The cells were incubated at 37˚C in a 5% CO 2 atmosphere and the culture medium was replaced every 2-4 days. The cells were liberated with trypsin-EDTA for subculture in new dishes with a subcultivation ratio of 1:2-1:3. Cells at passages 5-10 were used in all experiments.
MTT assay. The cells were seeded into 96-well plates (4,000 cells/well) and cultured to 70-80% confluence. Following incubation in DMEM with 0.01% FBS (Invitrogen; Thermo Fisher Scientific, Inc.) for 48 h, the cells were divided into different treatment groups, with six replicate wells for each treatment group. Following incubation at 37˚C for 6, 12, 24 or 48 h, 20 µl of MTT (5 mg/ml) was added to each well and the plates were incubated for an additional 4 h. Subsequently, the medium was discarded, and 100 µl of DMSO was added to each well and mixed thoroughly. The absorbance value of the wells was read at 490 nm using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Transfection and Zn treatment. For transfection, 150 nM of Nrf2 siRNA (sense, 5'-GAA GCC AGA UGU UAA GAA AUU-3'; antisense, 3'-UUC UUC GGU CUA CAA UUC UUU-5') or scrambled siRNA (sense, 5'UAG CGA CUA AAC ACA UCA AUU-3'; antisense, 3'UUA UCG CUG AUU UGU GUA GUU-5'; both GenePharma, Shanghai, China) was transfected into the HPMCs respectively, with Lipofectamine 2000. Following transfection for 24 h, the cells were treated with 10 µM ZnSO 4 at 37˚C for 24 h, followed by the incubation with 126 mM HG for an additional 24 h. To deplete intracellular Zn stores, the Zn chelator (TPEN; 1 µM) was added 4 h prior to the 24 h incubation with 126 mmol/l HG.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. The HPMCs were pretreated with 10 µM ZnSO 4 or 1 µM TPEN for 24 h and then incubated with 126 mM glucose for 24 h. The mRNA levels of NLRP3, caspase-1, heme oxygenase-1 (HO-1), NQO1, IL-1β and IL-18 were evaluated using RT-qPCR analysis. Total RNAs were isolated from the cells using TRIzol reagent and reverse transcription was performed using a Takara RNA PCR kit (Takara Bio, Inc., Otsu, Japan) according to the manufacturer's protocol. The qPCR was performed using SYBR Green Premix Ex Taq (Takara Bio, Inc.) on a Light Cycler 480 (Roche Diagnostics, Basel, Switzerland). β-actin mRNA was used as an internal control. The forward and reverse primers were as follows: β-actin, forward 5'-CTG TCC CTG TAT GCC TCT G- ELISA. The HPMCs were treated with medium alone or with 126 mM glucose in the presence or absence of ZnSO 4 or TPEN for 24 h. The cell culture media were centrifuged at 1,500 x g for 10 min at 4˚C and the supernatants were collected and stored at -20˚C prior to analysis. The levels of IL-1β and IL-18 in the supernatants were determined using a human IL-1β and IL-18 ELISA kit (R&D Systems, Inc.) according to the manufacturer's protocol.
Detection of intracellular ROS levels.
The HPMCs were treated with medium alone or with 126 mM glucose in the presence or absence of ZnSO 4 or TPEN for 24 h. The levels of ROS were determined using a ROS assay kit (Beyotime Institute of Biotechnology, Haimen, China) according to the manufacturer's protocol. Briefly, the HPMCs (5x10 6 ) were incubated with 10 µmol/l DCFH-DA probes at 37˚C for 30 min and washed with phosphate-buffered saline (PBS) three times in order to remove residual probes. DCFH-DA was deacetylated intracellularly using nonspecific esterase, which was further oxidized by ROS to the fluorescent compound 2,7-dichlorofluorescein (DCF). DCF fluorescence was detected using a flow cytometer (Miltenyi Biotec, Inc., Auburn, CA, USA). The results were analyzed using MACSQuantify™ Software version 5.2 (Miltenyi Biotec, Inc.).
Statistical analysis. All data are expressed as the mean ± standard deviation. Statistical analysis was performed using SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA). Comparisons among groups were performed using one-way analysis of variance. P<0.05 was considered to indicate a statistically significant difference. -1β and IL-18 . The HPMCs were treated with 76, 126 and 214 mM of glucose for 6, 12, 24 and 48 h, and the levels of IL-1β and IL-18 in the supernatant were detected by ELISA. As shown in Fig. 1 , at 24 and 48 h, the levels of the two cytokines increased significantly in a concentration-dependent manner following glucose treatment. However, the effect plateaued at the concentration of 126 mM for 24 h. Therefore, the HPMCs were treated with 126 mM glucose for 24 h in subsequent experiments.
Results

Effects of HG on the production of IL
Effects of Zn intervention on the viability of HPMCs cells.
As shown in Fig. 2 , Zn supplementation by ZnSO 4 for 24 h at concentrations ranging between 1 and 10 µM had no significant cytotoxic effect on the HPMCs cells. Therefore, ZnSO 4 at a concentration of 10 µM for 24 h was used in subsequent experiments. The inhibition of Zn by TPEN for 24 h at concentrations ranging between 0.1 and 1 µM had no significant cytotoxic effect on the HPMCs cells. Therefore, TPEN at a concentration of 1 µM for 24 h was used in subsequent experiments.
Zn inhibits HG-induced production of IL-1β and IL-18 in
HPMCs. The HPMCs were pretreated with 10 µM ZnSO 4 or 1 µM TPEN for 24 h and then incubated with 126 mM glucose for 24 h, following which the secretion of IL-1β and IL-18 in the supernatants of the HPMCs were examined by ELISA (Fig. 3A and B) . The mRNA expression levels of IL-1β and IL-18 in the HPMCs were detected using RT-qPCR analysis ( Fig. 3C and D) . The protein expression levels of pro-IL-1β, pro-IL-18, IL-1β, IL-18 in the HPMCs were detected using western blot analysis (Fig. 3E-G) . As shown in Fig. 3 , the HG-induced production of IL-1β and IL-18 was attenuated by pretreating the HPMCs with 10 µM ZnSO 4 . TPEN enhanced the effect of HG on the NLRP3 inflammasome in HPMCs.
Zn inhibits HG-induced NLRP3 inflammasome activation in the HPMCs.
The HPMCs were pretreated with 10 µM ZnSO 4 or 1 µM TPEN for 24 h, and then incubated with 126 mM glucose for 24 h. The protein expression levels of pro-caspase-1, caspase-1 and NLRP3 in the HPMCs were detected using western blot analysis (Fig. 4A-D) . The mRNA expression levels of caspase-1 and NLRP3 in the HPMCs were detected using RT-qPCR analysis (Fig. 4E and F) . Immunofluorescence was used to analyze the coexpression of ASC (green) and NLRP3 (red) in the HPMCs (Fig. 4G) . The HG-induced NLRP3 inflammasome activation was attenuated by pretreating the HPMCs with 10 µM ZnSO 4 , which was shown by the reduced expression of NLRP3 and caspase-1, and the reduced coexpression of NLRP3 and ASC. Pretreating the HPMCs with 1 µM TPEN further increased the expression of NLRP3 and caspase-1, and the coexpression of NLRP3 and ASC.
Zn inhibits HG-induced intracellular generation of ROS in
HPMCs. The HPMCs were pretreated with 10 µM ZnSO 4 or 1 µM TPEN for 24 h, and then incubated with 126 mM glucose for 24 h. The levels of intracellular ROS were detected using a DCFH-DA assay. As shown in Fig. 5A and B, the levels of ZnSO 4 promoted activation of the Nrf2-antioxidant system, whereas pretreatment with 1 µM TPEN reversed the activation of the Nrf2 antioxidant system induced by HG, as shown in Fig. 6 .
Zn inhibits HG-induced NLRP3 inflammasome activation by activating the Nrf2 antioxidant pathway in HPMCs.
Nrf2 siRNA or scrambled siRNA were transfected into HPMCs, following which the cells were pretreated with 10 µM ZnSO 4 or 1 µM TPEN for 24 h and then incubated with 126 mM glucose for 24 h. The NLRP3 inflammasome and Nrf2 antioxidant pathway activities were examined. As shown in Fig. 7 ZnSO 4 activated the Nrf2 antioxidant pathway and inhibited the NLRP3 inflammasome activation induced by HG. Silencing Nrf2 reversed the effect of ZnSO 4 on HG-induced NLRP3 inflammasome activation.
Discussion
Zn has been shown to effectively inhibit fibrosis, exhibiting antioxidant, antiapoptotic and anti-inflammatory properties (14, 16, 19) . Zn deficiency has been reported to be associated with NLRP3 inflammasome activation and the production of IL-1β in macrophages, however, the effect of Zn on HG-induced NLRP3 inflammasome activation in HPMCs remains to be fully elucidated. In the present study, it was found that HG induced NLRP3 inflammasome activation and the production of IL-1β and IL-18, consistent with the previous report (7) . Furthermore, the present study demonstrated for the first time, to the best of our knowledge, that Zn was important in protecting against NLRP3 inflammasome activation under HG conditions in HPMCs.
Canonical NLRP3 inflammasome activation has been reported to depend upon one, or a combination of signals, which include K + ion efflux, ROS generation and destabilization of lysosomal membranes. In the present study, data showed that HG caused ROS generation, which indicated that HG induced NLRP3 inflammasome activation by inducing the generation of ROS. The ability of Zn to retard oxidative processes has long been recognized. Accumulating evidence has demonstrated that Zn deficiency can trigger oxidative stress and oxidant-mediated damage to cell components (20) . By contrast, Zn supplementation is known to decrease oxidative stress by reducing ROS levels (21) . The data obtained in the present study suggested that Zn treatment attenuated HG-induced ROS generation, suggesting that Zn may inhibit HG-induced NLRP3 inflammasome activation by decreasing oxidative stress. The Nrf2 pathway is central in the antioxidant system. Under normal conditions, Nrf2 is captured by Kelch-like ECH-associated protein 1 (Keap1) in the cytoplasm, and is constantly degraded via the ubiquitin-proteasome pathway (22) . On exposure to excess ROS and Zn 2+ , Nrf2 dissociates from Keap1, accumulates in the nucleus, binds to antioxidant responsive element sequences (AREs) and activates antioxidant genes, including glutamate-cysteine ligase catalytic subunit and NQO1 (23, 24) . In the present study, the results indicated that HG induced the upregulation of nuclear Nrf2 and the target gene of the Nrf2 pathway. Zn treatment activated the Nrf2 pathway, which inhibited the HG-induced generation of ROS and NLRP3 inflammasome activation. The effects of Zn treatment on ROS generation and NLRP3 inflammasome activation were reduced by the knock down of Nrf2.
In conclusion, the present study demonstrated that HG induced NLRP3 inflammasome activation in HPMCs, whereas Zn treatment inhibited NLRP3 inflammasome activation by attenuating oxidative stress. Zn also inhibited oxidative stress by activating the Nrf2 pathway. These results indicated that Zn inhibited HG-induced NLRP3 inflammasome activation in HPMCs through activation of the Nrf2 antioxidant pathway. A more detailed understanding of the critical role of Zn is likely to provide insight at the molecular level into innovative therapeutic strategies for used in PD.
